Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo

• Status: Completed
• Trial end date: 2020-02-04
• Target enrollment: 0
• Participant gender: All

Summary

Patients with partial seizures currently taking 1-3 antiepileptic medications will have a 50:50 chance to receive Lyrica 300 mg per day or placebo (no active ingredients) added on to their current medications for 3 months. Neither the study doctor nor the patient will know the medication assignment. Vision testing will be performed prior to receiving the study treatment and at the end of the study to see if there are any changes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Pregabalin

Criteria

Inclusion Criteria:

• Epilepsy partial seizure subjects.

• Currently taking 1 to 3 antiepileptic drugs.

Exclusion Criteria:

• Pre-existing eye diseases (glaucoma).

• Insufficient response to pregabalin in the treatment of partial seizure, or patients currently receiving pregabalin treatment.